Log In
BCIQ
Print this Print this
 

A/H5N1 Avian Influenza Vaccine

Also known as: H5N1 VLP pandemic influenza vaccine

  Manage Alerts
Collapse Summary General Information
Company Novavax Inc.
DescriptionMonovalent virus-like particle (VLP) vaccine containing hemagglutinin (HA), neuraminidase (NA) and influenza A virus matrix protein M1 (M1) from the avian influenza virus
Molecular Target Not applicable
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Viral vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationInfluenza virus
Indication DetailsVaccinate against influenza virus
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$19.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/06/2009

$19.0M

0

0

Get a free BioCentury trial today